Intellectual Property

  • July 28, 2026

    Goodwin Grows Life Sciences Group With San Diego IP Hire

    Goodwin Procter LLP announced Monday that an experienced intellectual property attorney focused on life sciences matters has joined the firm's San Diego office as a partner from Wilson Sonsini Goodrich & Rosati PC.

  • July 28, 2026

    Pipe Inventor Says Other Parties Unneeded In Patent Suit

    The inventor of the Digger One Hitter smoking pipe is urging a Michigan federal court not to throw out his patent infringement claims against S&E Distributor Inc., saying the defendants are wrong to insist he has no right to sue.

  • July 27, 2026

    GoodPop, JonnyPops Trade Blows In Fruit Pop False Ad Fight

    GoodPop and JonnyPops have both filed summary judgment bids in a false advertising battle in Texas federal court that was filed two years ago by GoodPop, each arguing that their rival's claims over their respective frozen pops' fruit and sugar content can be tossed without going to trial.

  • July 27, 2026

    Fed. Circ. Clears Boston Scientific In $49M Stent Patent Case

    The Federal Circuit on Monday overturned a $49.4 million patent judgment against Boston Scientific, ruling that the company's drug-eluting coronary stents did not infringe a patent owned by the University of Texas System and that the patent is invalid.

  • July 27, 2026

    7th Circ. Asked To Clarify Copyright Prevailing Party Status

    A man who successfully defended himself from being held liable for damages when he was sued by a food photography company that claimed his photo of raw meat on Facebook counted as copyright infringement has asked the Seventh Circuit to find that he's the "prevailing party" for purposes of seeking attorney fees.

  • July 27, 2026

    Chobani Can't Escape Danone's Coffee TM Suit

    A New York federal judge on Monday refused to toss Danone's unregistered trademark infringement suit against Chobani over use of the phrase "Bright & Mellow," saying Danone plausibly backed up its argument that the mark was not simply generic.

  • July 27, 2026

    Verano Unit Accused Of Infringing Cannabis Extraction Patent

    A subsidiary of cannabis giant Verano Holdings LLC was hit with a patent infringement suit in Virginia federal court Monday accusing it of ripping off a California company's pioneering technology using safer, low-temperature ethanol extraction processes to obtain oils and compounds from cannabis, which helps avoid the risk of fires or explosions. 

  • July 27, 2026

    Consultant Says Fla. Co., Owner Stole Her Training Model

    A linguist claimed in a Florida federal court that the owner of a job consulting business breached their collaboration agreement and stole a training model she developed, alleging she wasn't given equity in the company as promised and that her copyrighted intellectual property was published in a book without her authorization.

  • July 27, 2026

    Google Can't Get 2nd Try At Eliminating Network-1 Patent

    A New York federal judge has denied Google's request for a second attempt at invalidating a patent asserted by a patent licensing company, rejecting its arguments that a Federal Circuit decision from last month made another try necessary.

  • July 27, 2026

    Yale, Biohaven Win $4M In Biotech Trade Secret Trial

    A Delaware federal jury has awarded Yale University and Biohaven Therapeutics $4 million after finding that venture capital firm RA Capital Management GP breached a confidentiality agreement and, along with co-defendant Avilar Therapeutics, misappropriated a Yale-developed trade secret for designing protein-degrading drug molecules.

  • July 27, 2026

    Samsung Owes $92.3M After Judge Boosts Media IP Award

    A Texas federal judge has heaped $13.8 million in prejudgment interest on top of a $78.5 million jury award owed by Samsung after it was found to infringe a pair of patents covering automatic content recognition technology for commercial advertising.

  • July 27, 2026

    AbbVie Seeks Block On Alkem Generic Constipation Drug

    AbbVie Inc. and collaborator Ironwood Pharmaceuticals urged a New Jersey federal court to bar India-based generic-drug maker Alkem Laboratories from selling generic versions of their branded constipation drug while associated patents are active, arguing Alkem would violate patent law by doing so.

  • July 27, 2026

    Ad Patent Claims Against Hulu Are Invalid, Judge Says

    A California federal judge has cleared Hulu from a lawsuit accusing it of infringing patents covering ways to deliver content and advertising through streaming, after finding the patents themselves were invalid to begin with.

  • July 27, 2026

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court last week tackled disputes involving restrictive covenants, corporate governance, trade secrets, real estate investments, receiverships, and books and records demands.

  • July 27, 2026

    NASCAR Says It's 'Overwhelmed' By 'Mass Counterfeiting'

    NASCAR is cracking down on counterfeit merchandise in a federal lawsuit filed Monday in North Carolina that seeks to block an alleged network of foreign retailers from selling knockoff clothing and collectibles through online marketplaces, social media platforms and search engines like Google.

  • July 27, 2026

    Stewart Leaving USPTO This Week For Private Sector Job

    Deputy U.S. Patent and Trademark Office Director Coke Morgan Stewart will leave the office this week to return to the private sector, she told the USPTO executive staff Monday in a message obtained by Law360.

  • July 27, 2026

    End Defamation Claim Against Baker Botts Atty, Court Advised

    A Florida federal magistrate judge has recommended that a defamation claim against a Baker Botts LLP patent attorney be tossed, saying an inventor hasn't shown that the lawyer's comments to a reporter at issue in the case were defamatory.

  • July 27, 2026

    Arnold & Porter Hires King & Spalding ITC-Focused Atty

    Arnold & Porter Kaye Scholer LLP has hired a King & Spalding LLP partner in Washington, D.C., who will continue his intellectual property work focused on the cross-border aspects of technology and life sciences disputes, the firm announced Monday.

  • July 24, 2026

    Phillips 66 Inks Deal To End Patent Case Revived By Fed. Circ.

    Phillips 66 has settled allegations it infringed Magema Technology's oil refinery patents, reaching a deal nearly a year after the Federal Circuit held that ordered a new trial in the yearslong battle.

  • July 24, 2026

    IP Cases In The Spotlight As ITC Adds 5 New Commissioners

    The Senate's confirmation of five new commissioners at the International Trade Commission, including two who were staffers on the intellectual property committees in Congress, could lead to a greater focus on IP cases at the commission and efforts to speed them up, attorneys say.

  • July 24, 2026

    Big Fish Can't Pursue Apple Store Takedown, Dev Says

    An Armenian game developer accused of withholding source code belonging to Big Fish Games urged a Washington federal judge Friday to block the company's attempt to have games removed from the Apple Store.

  • July 24, 2026

    Full Fed. Circ. Urged To Reconsider Pfizer's Paxlovid IP Win

    Enanta Pharmaceuticals is asking the Federal Circuit to rethink its June refusal to revive a patent it had asserted against Pfizer over its COVID-19 treatment Paxlovid, saying the court acted beyond its authority.

  • July 24, 2026

    Daily Beast Sued Over Image Of CEO In Viral Coldplay Incident

    A photographer sued the Daily Beast in New York federal court on Friday for using his image of Andy Byron, the former CEO of software company Astronomer who was caught in a viral "kiss cam" incident at a Coldplay concert.

  • July 24, 2026

    Finch Therapeutics Can Seek Ch. 11 Plan Votes

    A Delaware bankruptcy judge on Friday conditionally approved the disclosure statement for microbiome treatment developer Finch Therapeutics' Chapter 11 plan, allowing it to solicit creditor votes.

  • July 24, 2026

    Yale Age Test, Allergy Death, Wine Royalties: A Midyear Report

    In the second half of 2026, Connecticut courts are being called upon to decide closely watched issues such as whether the state's largest hospital group violated federal disability and age discrimination laws when requiring providers over age 70 to undergo mandatory cognitive tests.

Expert Analysis

  • What Artists Can Learn From Latest AI Music Licensing Deals

    Author Photo

    Recent partnerships between music labels and artificial intelligence companies raise a number of key questions for artists, rightsholders and other industry players about IP, revenue-sharing, and rights and obligations, say attorneys at Manatt.

  • If Your AI Vendor Goes Bankrupt: Keeping Licensed IP Access

    Author Photo

    With contracting norms still evolving to account for the licensing of artificial intelligence tools, customers that need to retain access to key AI products in the event of vendor’s bankruptcy should consider four elements that could determine whether they may invoke traditional Section 365(n) intellectual property protections, say attorneys at Sidley.

  • USPTO's New Patentability Focus Helps Emerging Tech

    Author Photo

    The U.S. Patent and Trademark Office's recent efforts to shift patentability criteria back toward traditional standards of novelty, obviousness and adequate disclosure should make it easier for emerging tech, including artificial intelligence, to obtain patents, says Bill Braunlin at Barclay Damon.

  • Malpractice Claim Assignability Continues To Divide Courts

    Author Photo

    Recent decisions from courts across the country demonstrate how different jurisdictions balance competing policy interests in determining whether legal malpractice claims can be assigned, providing a framework to identify when and how to challenge any attempted assignment, says Christopher Blazejewski at Sherin & Lodgen.

  • Tips For Financial Advisers Facing TRO From Former Firm

    Author Photo

    The Eighth Circuit's recent decision in Choreo v. Lors, overturning a lower court's sweeping injunction after financial advisers moved to a new firm, gives advisers new strategies to fight restraining orders from their old firms, such as focusing on whether the alleged irreparable harm is calculable, say attorneys at Kutak Rock.

  • Learning From A Typical Section 1782 Discovery Case

    Author Photo

    A California federal judge's recent approval of a Section 1782 application, compelling a U.S.-based company to produce materials relevant to a German patent dispute, usefully illustrates the specific steps foreign litigants must undertake before wielding this powerful tool for obtaining evidence unavailable via discovery mechanisms abroad, say attorneys at Fish & Richardson.

  • How To Trademark A Guy In 8 Ways: An IP Strategy Against AI

    Author Photo

    Attempting a novel method of protection against artificial intelligence misuse of his voice and likeness, Matthew McConaughey's recent efforts to register eight trademarks for a series of audio and video clips of himself underscore the importance of extending existing legal frameworks beyond traditional applications, says Summer Todd at Patterson Intellectual Property.

  • Utilizing The ITC To Combat 'Gray Market' IP Infringement

    Author Photo

    As technological developments intensify trademark owners' need to respond swiftly to "gray market" sales of international goods imported into the U.S. without the trademark owner's consent, litigating at the U.S. International Trade Commission offers an underutilized enforcement option, say attorneys at MoFo.

  • Series

    Teaching Logic Makes Me A Better Lawyer

    Author Photo

    Teaching middle and high school students the skills to untangle complicated arguments and identify faulty reasoning has made me reacquaint myself with the defined structure of thought, reminding me why logic should remain foundational in the practice of law, says Tom Barrow at Woods Rogers.

  • From IPR To EPR: The Rapid Rise Of Ex Parte Reexamination

    Author Photo

    With the current administration's dramatic shifts in policy rendering inter partes reviews essentially unavailable for the majority of patents being asserted in litigation, IPR filing rates have plunged, and ex parte reexamination requests have surged to the average rate of IPR petitions in 2024, say attorneys at McKool Smith.

  • Series

    Law School's Missed Lessons: Practicing Resilience

    Author Photo

    Resilience is a skill acquired through daily practices that focus on learning from missteps, recovering quickly without internalizing defeat and moving forward with intention, says Nicholas Meza at Quarles & Brady.

  • Upshot Of 'Skinny Label' Case May Go Beyond Pharma

    Author Photo

    The U.S. Supreme Court's pending review of Hikma v. Amarin, over a drugmaker's "skinny label," carries implications for both generics and brand-name pharmaceutical manufacturers, and could shed light on how inducement doctrine should operate in other regulated industries where products have substantial lawful uses, says Jason Shull at Banner Witcoff.

  • Assessing Factors Behind Biosimilar Uptake And Competition

    Author Photo

    As biosimilar uptake remains uneven and questions linger over whether the Biologics Price Competition and Innovation Act can deliver robust competition between biologics and biosimilars, a case study of Humira and its biosimilars illustrates how many factors, including payor reimbursement and formulary strategy, collectively shape competitive dynamics, say analysts at Analysis Group.

  • How 2 Tech Statutes Are Being Applied To Agentic AI

    Author Photo

    The application of the Computer Fraud and Abuse Act and the California Invasion of Privacy Act to agentic artificial intelligence is still developing, but recent case law, like Amazon's lawsuit against Perplexity in California federal court, provides some initial guidance for companies developing or deploying these technologies, say attorneys at Weil.

  • FTC Focus: Testing Joint Enforcement Over Loyalty Programs

    Author Photo

    The Federal Trade Commission's case against Syngenta can be understood both as a canary for further scrutiny over loyalty-discount practices and a signal of the durability of joint federal-state antitrust enforcement, with key takeaways for practitioners and those subject to regulatory antitrust scrutiny alike, say attorneys at Proskauer.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Intellectual Property archive.